NASDAQ:OLK

Olink Holding AB (publ) Competitors

$26.73
-3.55 (-11.72 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.00
$30.58
50-Day Range N/A
52-Week Range
$26.00
$42.20
Volume300,302 shs
Average Volume317,829 shs
Market Capitalization$3.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Olink Holding AB (publ) (NASDAQ:OLK) Vs. GDRX, GH, ICLR, RDY, MASI, and NVAX

Should you be buying OLK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Olink Holding AB (publ), including GoodRx (GDRX), Guardant Health (GH), ICON Public (ICLR), Dr. Reddy's Laboratories (RDY), Masimo (MASI), and Novavax (NVAX).

GoodRx (NASDAQ:GDRX) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for GoodRx and Olink Holding AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GoodRx16702.43
Olink Holding AB (publ)02202.50

GoodRx currently has a consensus price target of $51.50, suggesting a potential upside of 63.75%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than GoodRx.

Profitability

This table compares GoodRx and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GoodRxN/AN/AN/A
Olink Holding AB (publ)N/AN/AN/A

Institutional & Insider Ownership

43.4% of GoodRx shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GoodRx and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GoodRx$388.22 million31.77$66.05 millionN/AN/A
Olink Holding AB (publ)N/AN/AN/AN/AN/A

GoodRx has higher revenue and earnings than Olink Holding AB (publ).

Summary

GoodRx beats Olink Holding AB (publ) on 3 of the 5 factors compared between the two stocks.

Guardant Health (NASDAQ:GH) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Guardant Health and Olink Holding AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardant Health00903.00
Olink Holding AB (publ)02202.50

Guardant Health currently has a consensus price target of $170.50, suggesting a potential upside of 40.01%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than Guardant Health.

Profitability

This table compares Guardant Health and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardant Health-67.14%-19.22%-16.37%
Olink Holding AB (publ)N/AN/AN/A

Institutional & Insider Ownership

84.9% of Guardant Health shares are held by institutional investors. 13.0% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Guardant Health and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$214.38 million57.44$-75,650,000.00($0.84)-144.98
Olink Holding AB (publ)N/AN/AN/AN/AN/A

Olink Holding AB (publ) has lower revenue, but higher earnings than Guardant Health.

Summary

Guardant Health beats Olink Holding AB (publ) on 5 of the 9 factors compared between the two stocks.

ICON Public (NASDAQ:ICLR) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares ICON Public and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion4.31$373.99 million$6.8832.76
Olink Holding AB (publ)N/AN/AN/AN/AN/A

ICON Public has higher revenue and earnings than Olink Holding AB (publ).

Institutional & Insider Ownership

81.7% of ICON Public shares are held by institutional investors. 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ICON Public and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
Olink Holding AB (publ)N/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for ICON Public and Olink Holding AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public03702.70
Olink Holding AB (publ)02202.50

ICON Public currently has a consensus price target of $236.00, suggesting a potential upside of 4.71%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than ICON Public.

Summary

ICON Public beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88
Olink Holding AB (publ)N/AN/AN/AN/AN/A

Dr. Reddy's Laboratories has higher revenue and earnings than Olink Holding AB (publ).

Institutional and Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Olink Holding AB (publ)N/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dr. Reddy's Laboratories and Olink Holding AB (publ), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
Olink Holding AB (publ)02202.50

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, indicating a potential downside of 3.05%. Olink Holding AB (publ) has a consensus price target of $44.00, indicating a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts plainly believe Olink Holding AB (publ) is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Masimo and Olink Holding AB (publ), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02402.67
Olink Holding AB (publ)02202.50

Masimo presently has a consensus price target of $291.50, indicating a potential upside of 34.41%. Olink Holding AB (publ) has a consensus price target of $44.00, indicating a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts plainly believe Olink Holding AB (publ) is more favorable than Masimo.

Valuation and Earnings

This table compares Masimo and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million12.72$196.22 million$3.2267.35
Olink Holding AB (publ)N/AN/AN/AN/AN/A

Masimo has higher revenue and earnings than Olink Holding AB (publ).

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Masimo and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Olink Holding AB (publ)N/AN/AN/A

Summary

Masimo beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Olink Holding AB (publ) (NASDAQ:OLK) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Olink Holding AB (publ) and Novavax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olink Holding AB (publ)02202.50
Novavax10602.71

Olink Holding AB (publ) presently has a consensus target price of $44.00, indicating a potential upside of 64.61%. Novavax has a consensus target price of $229.6429, indicating a potential upside of 43.08%. Given Olink Holding AB (publ)'s higher probable upside, equities research analysts clearly believe Olink Holding AB (publ) is more favorable than Novavax.

Valuation & Earnings

This table compares Olink Holding AB (publ) and Novavax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olink Holding AB (publ)N/AN/AN/AN/AN/A
Novavax$18.66 million637.28$-132,690,000.00($5.80)-27.67

Olink Holding AB (publ) has higher earnings, but lower revenue than Novavax.

Institutional & Insider Ownership

49.9% of Novavax shares are owned by institutional investors. 3.3% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Olink Holding AB (publ) and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olink Holding AB (publ)N/AN/AN/A
Novavax-133.10%-1,346.17%-45.85%

Summary

Novavax beats Olink Holding AB (publ) on 5 of the 9 factors compared between the two stocks.


Olink Holding AB (publ) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GoodRx logo
GDRX
GoodRx
1.5$31.45-10.5%$12.33 billion$388.22 million0.00Upcoming Earnings
Analyst Report
Guardant Health logo
GH
Guardant Health
1.9$121.78-11.2%$12.31 billion$214.38 million-63.76Earnings Announcement
Analyst Report
Insider Selling
ICON Public logo
ICLR
ICON Public
2.0$225.39-1.5%$12.09 billion$2.81 billion37.57Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.20-1.6%$12.01 billion$2.32 billion59.67
Masimo logo
MASI
Masimo
1.8$216.88-3.4%$11.93 billion$937.84 million56.33
Novavax logo
NVAX
Novavax
1.6$160.50-9.7%$11.89 billion$18.66 million-30.75Insider Selling
Gap Down
Henry Schein logo
HSIC
Henry Schein
1.6$82.97-2.8%$11.67 billion$9.99 billion20.44Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25-1.5%$11.19 billion$16.89 billion-2.79Analyst Report
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.6$170.67-1.0%$11.06 billion$3.07 billion49.90Analyst Downgrade
QIAGEN logo
QGEN
QIAGEN
1.7$46.89-1.6%$10.69 billion$1.53 billion57.89
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10-0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53-2.0%$9.87 billion$8.60 billion-5.05Earnings Announcement
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$175.13-7.2%$9.62 billion$270.24 million213.57Earnings Announcement
Analyst Revision
Penumbra logo
PEN
Penumbra
1.7$263.37-3.1%$9.61 billion$547.41 million-975.44Earnings Announcement
Analyst Revision
Canopy Growth logo
CGC
Canopy Growth
1.1$24.18-4.5%$9.26 billion$297.34 million-7.24Analyst Revision
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.82-3.7%$9.23 billionN/A0.00News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.24-0.2%$8.63 billion$788.10 million98.11Earnings Announcement
Syneos Health logo
SYNH
Syneos Health
1.6$82.64-0.2%$8.62 billion$4.68 billion45.41
Encompass Health logo
EHC
Encompass Health
2.0$86.58-1.4%$8.62 billion$4.61 billion32.43Dividend Announcement
Amedisys logo
AMED
Amedisys
1.2$261.73-0.6%$8.53 billion$1.96 billion52.45
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88-2.9%$8.51 billion$1.45 billion17.96Earnings Announcement
Natera logo
NTRA
Natera
1.7$90.59-12.4%$7.94 billion$302.33 million-38.06Earnings Announcement
Analyst Report
Gap Down
Exelixis logo
EXEL
Exelixis
1.9$24.95-0.6%$7.81 billion$967.78 million51.98Earnings Announcement
Chemed logo
CHE
Chemed
2.2$489.50-0.1%$7.81 billion$1.94 billion29.68
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$101.46-6.2%$7.69 billion$289.59 million-31.12
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$147.63-2.5%$7.58 billion$3.34 million-19.17Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$27.67-5.1%$7.50 billionN/A0.00Upcoming Earnings
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$109.25-4.8%$7.37 billion$103.71 million-24.89Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Envista logo
NVST
Envista
1.1$45.28-0.4%$7.28 billion$2.75 billion-348.31Earnings Announcement
Analyst Upgrade
Analyst Revision
Hill-Rom logo
HRC
Hill-Rom
2.0$109.27-0.8%$7.26 billion$2.88 billion32.91Dividend Announcement
Analyst Report
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$75.71-1.0%$7.12 billion$10.68 million-41.15Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Globus Medical logo
GMED
Globus Medical
1.6$71.05-3.2%$7.09 billion$785.37 million77.23Earnings Announcement
Insider Selling
Analyst Revision
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.8$116.50-1.4%$7.07 billion$73.99 million-44.98Earnings Announcement
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$130.07-2.2%$6.99 billion$14.98 million-15.84
Change Healthcare logo
CHNG
Change Healthcare
1.0$22.73-0.7%$6.97 billion$3.20 billion-41.33Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$46.47-3.4%$6.94 billion$40.56 million-13.63Earnings Announcement
Analyst Report
Tenet Healthcare logo
THC
Tenet Healthcare
1.0$64.92-3.0%$6.93 billion$18.48 billion-499.38
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.10-0.4%$6.88 billion$87.99 million-78.69Earnings Announcement
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Sotera Health logo
SHC
Sotera Health
1.9$24.03-2.4%$6.80 billionN/A0.00Upcoming Earnings
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.10-3.2%$6.61 billion$195.99 million288.13Unusual Options Activity
News Coverage
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$51.57-5.3%$6.25 billion$26.68 million-23.33Analyst Revision
Gap Down
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$73.68-0.7%$6.23 billion$1.52 billion109.97
LHC Group logo
LHCG
LHC Group
1.7$196.34-2.5%$6.22 billion$2.08 billion59.68Earnings Announcement
Analyst Revision
News Coverage
HealthEquity logo
HQY
HealthEquity
1.6$71.79-3.8%$5.96 billion$531.99 million1,436.09Analyst Revision
Perrigo logo
PRGO
Perrigo
2.2$43.12-0.4%$5.76 billion$4.84 billion-718.55Upcoming Earnings
News Coverage
Medpace logo
MEDP
Medpace
1.2$158.82-4.1%$5.71 billion$860.97 million48.57
Acadia Healthcare logo
ACHC
Acadia Healthcare
1.0$63.42-0.9%$5.69 billion$3.11 billion56.12Analyst Report
Omnicell logo
OMCL
Omnicell
1.7$129.91-8.9%$5.61 billion$897.03 million149.32
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.03-6.5%$5.59 billion$380.83 million-8.96Earnings Announcement
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.